-- Seed file for documents
-- This file creates sample documents for development and testing

INSERT INTO documents (
    uuid,
    title,
    url,
    document_type,
    description,
    upload_date,
    uploaded_by,
    trial_uuid,
    site_uuid,
    created_at
) VALUES 
-- CARDIO-PROTECT Trial Documents
('ee0e8400-e29b-41d4-a716-446655440001', 'CARDIO-PROTECT Clinical Study Protocol v2.1', '/documents/trials/cardio-protect/protocol_v2.1.pdf', 'Protocol', 'Complete clinical study protocol including objectives, methodology, statistical analysis plan, and safety monitoring procedures for the CARDIO-PROTECT trial evaluating novel ACE inhibitor in heart failure patients.', '2024-12-15', '550e8400-e29b-41d4-a716-446655440001', '770e8400-e29b-41d4-a716-446655440001', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440002', 'Patient Informed Consent Form - English', '/documents/trials/cardio-protect/icf_english_v1.3.pdf', 'InformedConsent', 'Informed consent document for English-speaking patients participating in the CARDIO-PROTECT trial, including detailed information about study procedures, risks, benefits, and patient rights.', '2025-01-10', '550e8400-e29b-41d4-a716-446655440006', '770e8400-e29b-41d4-a716-446655440001', '880e8400-e29b-41d4-a716-446655440001', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440003', 'EMA Clinical Trial Authorization', '/documents/trials/cardio-protect/ema_authorization.pdf', 'RegulatoryApproval', 'Official authorization from the European Medicines Agency for conducting the CARDIO-PROTECT clinical trial across multiple European sites with approval conditions and reporting requirements.', '2024-11-30', '550e8400-e29b-41d4-a716-446655440014', '770e8400-e29b-41d4-a716-446655440001', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440004', 'Investigator Brochure v3.2', '/documents/trials/cardio-protect/investigator_brochure_v3.2.pdf', 'Other', 'Comprehensive investigator brochure containing preclinical and clinical data for the investigational ACE inhibitor, including pharmacology, safety profile, and dosing recommendations.', '2024-10-15', '550e8400-e29b-41d4-a716-446655440001', '770e8400-e29b-41d4-a716-446655440001', NULL, CURRENT_TIMESTAMP),

-- ONCO-TARGET Trial Documents
('ee0e8400-e29b-41d4-a716-446655440005', 'ONCO-TARGET Protocol Amendment 1', '/documents/trials/onco-target/protocol_amendment_1.pdf', 'Protocol', 'First amendment to the ONCO-TARGET protocol incorporating updated biomarker stratification criteria and modified primary endpoint assessment schedule based on interim safety data.', '2024-08-20', '550e8400-e29b-41d4-a716-446655440002', '770e8400-e29b-41d4-a716-446655440002', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440006', 'Biomarker Analysis Plan', '/documents/trials/onco-target/biomarker_analysis_plan.pdf', 'Other', 'Detailed statistical analysis plan for biomarker endpoints including next-generation sequencing protocols, mutation analysis procedures, and correlation with clinical outcomes.', '2024-07-15', '550e8400-e29b-41d4-a716-446655440013', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440004', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440007', 'Patient Information Sheet - German', '/documents/trials/onco-target/patient_info_german_v1.1.pdf', 'InformedConsent', 'German language patient information sheet for ONCO-TARGET trial participants at German sites, including simplified explanation of precision medicine approach and genetic testing.', '2024-08-30', '550e8400-e29b-41d4-a716-446655440007', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440004', CURRENT_TIMESTAMP),

-- NEURO-SHIELD Trial Documents
('ee0e8400-e29b-41d4-a716-446655440008', 'NEURO-SHIELD Study Manual', '/documents/trials/neuro-shield/study_manual_v1.2.pdf', 'Other', 'Comprehensive study manual for NEURO-SHIELD trial including detailed procedures for neurological assessments, cognitive testing protocols, and biomarker collection procedures.', '2024-10-01', '550e8400-e29b-41d4-a716-446655440001', '770e8400-e29b-41d4-a716-446655440003', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440009', 'Cognitive Assessment Battery Instructions', '/documents/trials/neuro-shield/cognitive_assessment_manual.pdf', 'Other', 'Detailed instructions for conducting standardized cognitive assessments in NEURO-SHIELD trial including UPDRS, MoCA, and custom Parkinson-specific cognitive battery.', '2024-10-15', '550e8400-e29b-41d4-a716-446655440008', '770e8400-e29b-41d4-a716-446655440003', '880e8400-e29b-41d4-a716-446655440007', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440010', 'French Ethics Committee Approval', '/documents/trials/neuro-shield/french_ethics_approval.pdf', 'RegulatoryApproval', 'Approval letter from the French ethics committee (CPP) for conducting NEURO-SHIELD trial at French sites with specific conditions and reporting requirements.', '2024-09-15', '550e8400-e29b-41d4-a716-446655440014', '770e8400-e29b-41d4-a716-446655440003', '880e8400-e29b-41d4-a716-446655440007', CURRENT_TIMESTAMP),

-- DIABETES-NEXT Trial Documents (Planning phase)
('ee0e8400-e29b-41d4-a716-446655440011', 'DIABETES-NEXT Protocol Draft v0.9', '/documents/trials/diabetes-next/protocol_draft_v0.9.pdf', 'Protocol', 'Draft protocol for DIABETES-NEXT trial evaluating advanced glucose control technology in Type 1 diabetes patients, currently under internal review before regulatory submission.', '2025-02-01', '550e8400-e29b-41d4-a716-446655440002', '770e8400-e29b-41d4-a716-446655440004', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440012', 'Health Economics Endpoints Plan', '/documents/trials/diabetes-next/health_economics_plan.pdf', 'Other', 'Detailed plan for health economics and quality of life endpoints in DIABETES-NEXT trial including validated questionnaires and cost-effectiveness analysis framework.', '2025-01-20', '550e8400-e29b-41d4-a716-446655440013', '770e8400-e29b-41d4-a716-446655440004', NULL, CURRENT_TIMESTAMP),

-- BREATHE-EASY Trial Documents (Completed)
('ee0e8400-e29b-41d4-a716-446655440013', 'BREATHE-EASY Final Study Report', '/documents/trials/breathe-easy/final_study_report.pdf', 'Other', 'Comprehensive final study report for completed BREATHE-EASY trial including efficacy and safety results, statistical analysis, and regulatory conclusions for COPD treatment.', '2025-02-15', '550e8400-e29b-41d4-a716-446655440013', '770e8400-e29b-41d4-a716-446655440005', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440014', 'Pulmonary Function Testing Manual', '/documents/trials/breathe-easy/pft_manual.pdf', 'Other', 'Standardized procedures for pulmonary function testing in BREATHE-EASY trial including spirometry protocols, quality control measures, and normal value references.', '2023-05-15', '550e8400-e29b-41d4-a716-446655440004', '770e8400-e29b-41d4-a716-446655440005', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440015', 'BREATHE-EASY CSR Statistical Appendix', '/documents/trials/breathe-easy/csr_statistical_appendix.pdf', 'Other', 'Detailed statistical appendix to the Clinical Study Report containing all statistical outputs, analysis datasets, and methodology documentation for regulatory submission.', '2025-02-20', '550e8400-e29b-41d4-a716-446655440013', '770e8400-e29b-41d4-a716-446655440005', NULL, CURRENT_TIMESTAMP),

-- Cross-trial regulatory documents
('ee0e8400-e29b-41d4-a716-446655440016', 'GDPR Data Processing Agreement', '/documents/regulatory/gdpr_dpa_cardio_protect.pdf', 'Other', 'Data processing agreement for CARDIO-PROTECT trial compliant with GDPR requirements, defining roles and responsibilities for data handling across multiple European sites.', '2024-12-01', '550e8400-e29b-41d4-a716-446655440014', '770e8400-e29b-41d4-a716-446655440001', NULL, CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440017', 'Quality Management Plan', '/documents/quality/qmp_onco_target.pdf', 'Other', 'Comprehensive quality management plan for ONCO-TARGET trial including quality assurance procedures, audit schedules, and corrective action protocols.', '2024-07-01', '550e8400-e29b-41d4-a716-446655440011', '770e8400-e29b-41d4-a716-446655440002', NULL, CURRENT_TIMESTAMP),

-- Training and certification documents
('ee0e8400-e29b-41d4-a716-446655440018', 'Site Staff Training Materials', '/documents/training/cardio_protect_training.pdf', 'Other', 'Comprehensive training materials for site staff conducting CARDIO-PROTECT trial including GCP training, protocol-specific procedures, and emergency contact information.', '2024-12-10', '550e8400-e29b-41d4-a716-446655440009', '770e8400-e29b-41d4-a716-446655440001', '880e8400-e29b-41d4-a716-446655440002', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440019', 'Investigator GCP Certificates', '/documents/training/gcp_certificates_neuro.pdf', 'Other', 'Collection of Good Clinical Practice certificates for principal investigators participating in NEURO-SHIELD trial, demonstrating compliance with ICH-GCP guidelines.', '2024-09-01', '550e8400-e29b-41d4-a716-446655440010', '770e8400-e29b-41d4-a716-446655440003', '880e8400-e29b-41d4-a716-446655440008', CURRENT_TIMESTAMP),

-- Emergency procedures and safety documents
('ee0e8400-e29b-41d4-a716-446655440020', 'Serious Adverse Event Reporting Procedures', '/documents/safety/sae_reporting_onco_target.pdf', 'Other', 'Detailed procedures for reporting serious adverse events in ONCO-TARGET trial including timelines, contact information, and reporting forms for regulatory authorities.', '2024-08-15', '550e8400-e29b-41d4-a716-446655440009', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440005', CURRENT_TIMESTAMP),

-- Site-specific documents
('ee0e8400-e29b-41d4-a716-446655440021', 'Amsterdam UMC - Local Laboratory Procedures', '/documents/sites/amsterdam-umc/lab_procedures_cardio.pdf', 'Other', 'Site-specific laboratory procedures for CARDIO-PROTECT trial at University Medical Center Amsterdam including sample collection, processing, and shipping protocols.', '2025-01-20', '550e8400-e29b-41d4-a716-446655440006', '770e8400-e29b-41d4-a716-446655440001', '880e8400-e29b-41d4-a716-446655440001', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440022', 'Charité Berlin - German ICF Translation', '/documents/sites/charite-berlin/icf_german_cardio.pdf', 'InformedConsent', 'German translation of informed consent form for CARDIO-PROTECT trial at Charité Berlin, reviewed and approved by local ethics committee.', '2025-01-15', '550e8400-e29b-41d4-a716-446655440007', '770e8400-e29b-41d4-a716-446655440001', '880e8400-e29b-41d4-a716-446655440002', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440023', 'AP-HP Paris - Local Ethics Approval', '/documents/sites/ap-hp-paris/ethics_approval_cardio.pdf', 'RegulatoryApproval', 'Local ethics committee approval for CARDIO-PROTECT trial at Assistance Publique - Hôpitaux de Paris with site-specific conditions and monitoring requirements.', '2025-01-18', '550e8400-e29b-41d4-a716-446655440014', '770e8400-e29b-41d4-a716-446655440001', '880e8400-e29b-41d4-a716-446655440003', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440024', 'Netherlands Cancer Institute - Biobank Agreement', '/documents/sites/nci-amsterdam/biobank_agreement_onco.pdf', 'Other', 'Biobank agreement for ONCO-TARGET trial at Netherlands Cancer Institute covering sample storage, future use, and patient consent for biomarker research.', '2024-09-10', '550e8400-e29b-41d4-a716-446655440006', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440005', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440025', 'Institut Gustave Roussy - French ANSM Approval', '/documents/sites/igr-villejuif/ansm_approval_onco.pdf', 'RegulatoryApproval', 'French ANSM (Agence Nationale de Sécurité du Médicament) approval for ONCO-TARGET trial at Institut Gustave Roussy with specific conditions for precision medicine study.', '2024-09-25', '550e8400-e29b-41d4-a716-446655440014', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440006', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440026', 'Salpêtrière Hospital - Neurology Equipment Certification', '/documents/sites/salpetriere-paris/equipment_cert_neuro.pdf', 'Other', 'Certification documents for specialized neurological assessment equipment at Salpêtrière Hospital for NEURO-SHIELD trial including calibration records and maintenance schedules.', '2024-10-30', '550e8400-e29b-41d4-a716-446655440008', '770e8400-e29b-41d4-a716-446655440003', '880e8400-e29b-41d4-a716-446655440007', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440027', 'VU Medical Center - Dutch Patient Information Sheet', '/documents/sites/vu-amsterdam/patient_info_dutch_neuro.pdf', 'InformedConsent', 'Dutch language patient information sheet for NEURO-SHIELD trial at VU Medical Center, adapted for local patient population and regulatory requirements.', '2024-11-10', '550e8400-e29b-41d4-a716-446655440006', '770e8400-e29b-41d4-a716-446655440003', '880e8400-e29b-41d4-a716-446655440008', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440028', 'Diabeter Rotterdam - Pediatric Study Procedures', '/documents/sites/diabeter-rotterdam/pediatric_procedures_diabetes.pdf', 'Other', 'Specialized procedures for pediatric and adolescent participants in DIABETES-NEXT trial at Diabeter Center including age-appropriate consent processes and safety monitoring.', '2025-02-10', '550e8400-e29b-41d4-a716-446655440006', '770e8400-e29b-41d4-a716-446655440004', '880e8400-e29b-41d4-a716-446655440009', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440029', 'Berlin Institute - Quality Assurance Plan', '/documents/sites/berlin-respiratory/qa_plan_breathe_easy.pdf', 'Other', 'Site-specific quality assurance plan for BREATHE-EASY trial at Berlin Institute for Respiratory Medicine including monitoring schedules and data verification procedures.', '2023-05-20', '550e8400-e29b-41d4-a716-446655440007', '770e8400-e29b-41d4-a716-446655440005', '880e8400-e29b-41d4-a716-446655440010', CURRENT_TIMESTAMP),
('ee0e8400-e29b-41d4-a716-446655440030', 'Charité Cancer Center - Molecular Lab Procedures', '/documents/sites/charite-cancer/molecular_lab_onco.pdf', 'Other', 'Detailed molecular laboratory procedures for ONCO-TARGET trial at Charité Cancer Center including NGS protocols, mutation analysis workflows, and quality control measures.', '2024-09-05', '550e8400-e29b-41d4-a716-446655440007', '770e8400-e29b-41d4-a716-446655440002', '880e8400-e29b-41d4-a716-446655440004', CURRENT_TIMESTAMP)

ON CONFLICT (uuid) DO NOTHING;
